GZD856

CAT: 0804-HY-101489Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-101489Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity[1][2].
CAS Number
[1257628-64-0]
UNSPSC
12352005
Target
Apoptosis; Bcr-Abl; PDGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/GZD856.html
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN5C(N=C4)=CC=N5)=C3
Molecular Formula
C29H27F3N6O
Molecular Weight
532.56
References & Citations
[1]Zhang Z, et al. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Lett. 2016 May 28;375 (1) :172-178.|[2]Lu X, et al. Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance. J Enzyme Inhib Med Chem. 2017 Dec;32 (1) :331-336.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcr-Abl; PDGFRα; PDGFRβ

Related Products

CatalogName

Alternative Products

CatalogName
MBS3844791-01GZD856
A20345-25GZD856 25mg
A20345-1GZD856 1mg
A20345-10GZD856 10mg
A20345-50GZD856 50mg
A20345-100GZD856 100mg
T64087-01GZD856 formic
A20345-5GZD856 5mg

Popular Products